ClinicalTrials.govpublic full text
Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma
upper tract urothelial carcinoma, utuc, her2, disitamab vedotin, radiotherapy, adjuvant therapy, cisplatin-ineligible, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 873620
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.